US Patent

US8658641 — Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections

Composition of Matter · Assigned to AstraZeneca AB · Expires 2030-06-20 · 4y remaining

Vulnerability score 23/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel compounds of Formula (I) and their pharmaceutically acceptable salts for treating bacterial infections.

USPTO Abstract

The present invention relates to compounds of Formula (I); to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation.

Drugs covered by this patent

zoliflodacin (ZOLIFLODACIN)

Patent Metadata

Patent number: US8658641
Jurisdiction: US
Classification: Composition of Matter
Expires: 2030-06-20
Drug substance claim: Yes
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.